Estrella Immunopharma, Inc.
ESLA
$0.64
$0.00-0.36%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -0.62% | -273.79% | 87.23% | 13.41% | -163.50% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 43.91% | 113.64% | -45.56% | 37.96% | 0.00% |
| Change in Net Operating Assets | 103.39% | -1,574.16% | -91.80% | -22.46% | 236.05% |
| Cash from Operations | 73.41% | -3,673.52% | 75.59% | -75.30% | 10.97% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -- | -100.00% | -22.22% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -1,071.14% | -410.24% | 68.25% | -- |
| Cash from Financing | -100.00% | 11,274.54% | -106.25% | -20.82% | 4,540.68% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -427.88% | 324.14% | -178.16% | -65.37% | 280.68% |